WuXi and I-Mab extend partnership to accelerate biologic development

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags: Wuxi, Wuxi biologics, I-Mab, Monoclonal antibody, CMC, Biologics, Bispecific antibodies

I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.

Per the extended collaboration, I-Mab, a China-based biotech focusing on biologics for immuno-oncology and auto-immune diseases through its R&D capabilities, will use WuXi’s chemistry, manufacturing, and control (CMC) development platform.

I-Mab will tap Hong Kong-based WuXi’s CMC expertise for at least five of its biologics programs, and commercial manufacturing for one program in its monoclonal antibody (mAb), bispecific antibody, and fusion protein pipelines. 

Through the 3-year partnership, I-Mab expects to see the acceleration of its pipeline’s development in China and abroad. I-Mab’s president Zheru Zhang said in a statement that the company “will be able to expedite our potential first-in-class and best-in-class biologics to the market to satisfy substantial unmet medical needs with high quality and speed.”

WuXi Biologics stated it will use its business strategy of ‘follow-the-molecule’ in this partnership. A spokesperson for WuXi told us that this strategy focuses on following the customers’ demand for its services to advance biologics through development. This enables WuXi’s revenue to ​grow geometrically’ while projects advance through the development cycle, they said

Additionally, WuXi stated that the partnership follows its global dual sourcing plan in which its partner selects the facilities from its global supply network in China, the EU, and the US to “ensure their global supply and eliminate the risks of inter-company technology transfer.”

Related news

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars